Miranda Jayne Toledano - 04 Apr 2023 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Executive Officer, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Issuer symbol: ENTX
Transactions as of: 04 Apr 2023
Net transactions value: +$30,300
Form type: 4
Filing time: 06 Apr 2023, 16:05:43 UTC
Previous filing: 14 Nov 2022
Next filing: 25 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	$30,300	+30,000	+53%	$1.01	86,800	04 Apr 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4976 to $0.55, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4976 to $0.55, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.